Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 1.28 USD -2.29%
Market Cap: 235.6m USD
Have any thoughts about
Nektar Therapeutics?
Write Note

Wall Street
Price Targets

NKTR Price Targets Summary
Nektar Therapeutics

Wall Street analysts forecast NKTR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NKTR is 2.7 USD with a low forecast of 1.31 USD and a high forecast of 4.2 USD.

Lowest
Price Target
1.31 USD
3% Upside
Average
Price Target
2.7 USD
111% Upside
Highest
Price Target
4.2 USD
228% Upside
Nektar Therapeutics Competitors:
Price Targets
AJANTPHARM
Ajanta Pharma Ltd
2% Downside
SNDL
Sundial Growers Inc
90% Upside
SHE
Shedir Pharma Srl Unipersonale
68% Upside
BSEM
Biostem Technologies Inc
25% Upside
605116
Aurisco Pharmaceutical Co Ltd
43% Upside

Revenue
Forecast

Revenue Estimate
Nektar Therapeutics

For the last 8 years the compound annual growth rate for Nektar Therapeutics's revenue is -11%. The projected CAGR for the next 3 years is -3%.

-11%
Past Growth
-3%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Nektar Therapeutics

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Nektar Therapeutics

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NKTR's stock price target?
Price Target
2.7 USD

According to Wall Street analysts, the average 1-year price target for NKTR is 2.7 USD with a low forecast of 1.31 USD and a high forecast of 4.2 USD.

What is Nektar Therapeutics's Revenue forecast?
Projected CAGR
-3%

For the last 8 years the compound annual growth rate for Nektar Therapeutics's revenue is -11%. The projected CAGR for the next 3 years is -3%.

Back to Top